FREE EMAIL WATCHDOG

Get free email notifications about news in Alliqua BioMedical, Inc..

The service is free and you can unsubscribe at any time.

General | People (106) | Filings (704) | Investment rounds (19) | Annual reports (7) | Stock | News

Alliqua BioMedical, Inc. SEC Filing Form 8-K Current report 2/2017, submited: 2017-06-19

<< back to list of filings

Form 8-K

An 8-K is a report of unscheduled material events or corporate changes at a company that could be of importance to the shareholders or the Securities and Exchange Commission.

Examples of events reported on an 8-K include acquisition, bankruptcy, resignation of directors, or a change in the fiscal year. Also known as Form 8k.

8-K 1 v469018_8k.htm 8-K

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

 

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

 

 

Date of Report (Date of earliest event reported): June 19, 2017

 

Alliqua BioMedical, Inc.

 

(Exact Name of Registrant as Specified in its Charter)

 

Delaware

 

001-36278

 

58-2349413

(State or other
jurisdiction
of incorporation)
  (Commission File Number)   (IRS Employer
Identification No.)

 

1010 Stony Hill Road

Suite 200

Yardley, Pennsylvania

 

19067

(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (215) 702-8550

 

 

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4 (c) under the Exchange Act (17 CFR 240.13e-4(c)

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

Item 1.01Other Events.

 

On June 19, 2017, Alliqua BioMedical, Inc. (the “Company”) announced that it has entered into a partnership with Partners Capital Group to provide the Company’s potential UltraMIST customers with new equipment financing programs. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is hereby incorporated by reference herein.

 

Item 9.01Financial Statements and Exhibits.

 

(d)     Exhibits

 

Exhibit
Number
  Description
99.1   Press release dated June 19, 2017.

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  ALLIQUA BIOMEDICAL, INC.
     
Dated: June 19, 2017 By: /s/ Brian Posner
    Name: Brian Posner
    Title: Chief Financial Officer

 

 

 

Alliqua BioMedical, Inc. Latest filings

Filing dateCompanyFormQuarterYear
2017-10-05Alliqua BioMedical, Inc.8-K42017view
2017-09-25Alliqua BioMedical, Inc.432017view
2017-09-25Alliqua BioMedical, Inc.432017view
2017-09-25Alliqua BioMedical, Inc.432017view
2017-09-13Alliqua BioMedical, Inc.8-K32017view
2017-09-05Alliqua BioMedical, Inc.8-K32017view
2017-09-01Alliqua BioMedical, Inc.8-K32017view
2017-08-10Alliqua BioMedical, Inc.10-Q32017view
2017-08-10Alliqua BioMedical, Inc.8-K32017view
2017-08-07Alliqua BioMedical, Inc.DEF 14A32017view